Stonegate Capital Partners has initiated coverage on Medicus Pharma Ltd. (NASDAQ: MDCX), a company advancing a diversified portfolio of clinical and pre-clinical assets. The coverage comes as Medicus executes a multi-strategy approach combining organic development with opportunistic acquisitions to accelerate its therapeutic pipeline.
In the second quarter of 2025, Medicus completed the acquisition of Antev Limited, expanding into dermatology and infectious diseases. This complements its lead program, SkinJect, a dissolvable microneedle patch for localized chemotherapy delivery to treat non-melanoma skin cancers such as basal cell carcinoma. The patch is designed for outpatient use, potentially reducing costs and improving patient compliance versus surgical or systemic treatments.
Medicus also entered into a Memorandum of Understanding with Helix Nanotechnologies to co-develop thermostable vaccines for infectious diseases. This collaboration addresses critical global healthcare challenges tied to cold-chain limitations, particularly relevant for vaccine distribution in underserved regions.
Financially, the company secured an $8.0 million non-dilutive debenture financing, strengthening its balance sheet and extending cash runway while minimizing shareholder dilution. Cash and equivalents stood at $9.7 million at quarter-end, up from $4.2 million at year-end 2024, supported by equity raises, warrant exercises, and debenture proceeds. Management expects sufficient capital to advance ongoing programs into 2026.
For the second quarter of 2025, Medicus reported a net loss of $6.2 million, compared to $3.6 million in the same period last year, reflecting increased expenses of $4.6 million and R&D investment of $1.4 million. The six-month net loss widened to $11.3 million versus $5.3 million in the prior year, consistent with expanded development activities.
Stonegate's valuation uses a probability-adjusted discounted cash flow model, yielding a range of $14.91 to $29.35 per share with a midpoint of $21.13, based on discount rates of 17.50% to 22.50% and risk adjustments of 50% to 40%. The model is highly levered to out-year projections due to the long-term nature of the industry, allowing for potential re-ratings as new information emerges.
Medicus continues to pursue additional high-impact assets to complement its portfolio, leveraging its multi-strategy model. The company's initiatives highlight a focus on both near-term specialty indications and longer-term global opportunities. For more details, refer to Stonegate's full report on page 9.
